Cancer company Rgenix raises $40M series C

Rgenix Inc. (New York, N.Y.) raised $40 million on Oct. 9 in a series C round led by Lepu Medical. New investors Oceanpine Capital and the corporate venture fund of WuXi AppTec Co. Ltd. (Shanghai:603259) also participated, as did existing investors Novo Holdings A/S (Hellerup, Denmark), Sofinnova Partners, Alexandria Venture Investments, the Partnership Fund for New York City’s Innovate NY Fund and associated entities.

Rgenix said the financing will support Phase Ib/II trials of lead candidate RGX-104 in multiple cancer indications, including in checkpoint refractory patients. The compound is in a Phase Ib trial to treat advanced solid malignancies and lymphoma as monotherapy and in combination with the PD-1 mAb Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) and Ono Pharmaceutical Co. Ltd. (Tokyo:4528). RGX-104 is a small molecule agonist of liver X receptor β (NR1H2; LXR-b)...